FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA

Aim. To investigate the effects of fluvastatin on the blood cell aggregation in patients with arterial hypertension (AH) and dyslipidemia (DLP).Material and methods. The main group (MG) included 32 middle-aged patients with Stage 1–2 AH (Risk 3) and Type IIb DLP. The control group (CG) included 26 h...

Full description

Bibliographic Details
Main Authors: I. N. Medvedev, I. A. Skoryatina
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2013-04-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/150
id doaj-c782df5aec104a628d506d87a3de938f
record_format Article
spelling doaj-c782df5aec104a628d506d87a3de938f2021-07-28T13:50:56Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252013-04-01122182410.15829/1728-8800-2013-2-18-24150FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIAI. N. Medvedev0I. A. Skoryatina1Kursk Institute of Social Education, Russian State Social University, KurskKursk Institute of Social Education, Russian State Social University, KurskAim. To investigate the effects of fluvastatin on the blood cell aggregation in patients with arterial hypertension (AH) and dyslipidemia (DLP).Material and methods. The main group (MG) included 32 middle-aged patients with Stage 1–2 AH (Risk 3) and Type IIb DLP. The control group (CG) included 26 healthy middle-aged people. All patients received fluvastatin (40 mg/d in the evening) and enalapril (10 mg twice per day). The assessment of clinical and laboratory parameters was performed at baseline, and after 4, 12, and 52 weeks of the therapy.Results. In MG patients, the disturbances of blood lipid profile and lipid component of blood cell membranes, together with activation of lipid peroxidation (LP) in blood cell membranes, was associated with an increased aggregation of erythrocytes, platelets, and leukocytes. The 52-week fluvastatin therapy somewhat improved blood lipid profile and reduced LP activity in both plasma and blood cells. However, these parameters failed to reach the levels observed in the CG. The one-year treatment with fluvastatin in the MG reduced, but not completely normalised the aggregation of erythrocytes, platelets, and leukocytes.Conclusion. Treating patients with AH and DLP with fluvastatin for one year significantly reduces, but not normalises blood cell aggregation.https://cardiovascular.elpub.ru/jour/article/view/150arterial hypertensiondyslipidemiafluvastatinaggregation activityblood cells
collection DOAJ
language Russian
format Article
sources DOAJ
author I. N. Medvedev
I. A. Skoryatina
spellingShingle I. N. Medvedev
I. A. Skoryatina
FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
Кардиоваскулярная терапия и профилактика
arterial hypertension
dyslipidemia
fluvastatin
aggregation activity
blood cells
author_facet I. N. Medvedev
I. A. Skoryatina
author_sort I. N. Medvedev
title FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
title_short FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
title_full FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
title_fullStr FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
title_full_unstemmed FLUVASTATIN EFFECTS ON BLOOD CELL AGGREGATION IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
title_sort fluvastatin effects on blood cell aggregation in patients with arterial hypertension and dyslipidemia
publisher «SILICEA-POLIGRAF» LLC
series Кардиоваскулярная терапия и профилактика
issn 1728-8800
2619-0125
publishDate 2013-04-01
description Aim. To investigate the effects of fluvastatin on the blood cell aggregation in patients with arterial hypertension (AH) and dyslipidemia (DLP).Material and methods. The main group (MG) included 32 middle-aged patients with Stage 1–2 AH (Risk 3) and Type IIb DLP. The control group (CG) included 26 healthy middle-aged people. All patients received fluvastatin (40 mg/d in the evening) and enalapril (10 mg twice per day). The assessment of clinical and laboratory parameters was performed at baseline, and after 4, 12, and 52 weeks of the therapy.Results. In MG patients, the disturbances of blood lipid profile and lipid component of blood cell membranes, together with activation of lipid peroxidation (LP) in blood cell membranes, was associated with an increased aggregation of erythrocytes, platelets, and leukocytes. The 52-week fluvastatin therapy somewhat improved blood lipid profile and reduced LP activity in both plasma and blood cells. However, these parameters failed to reach the levels observed in the CG. The one-year treatment with fluvastatin in the MG reduced, but not completely normalised the aggregation of erythrocytes, platelets, and leukocytes.Conclusion. Treating patients with AH and DLP with fluvastatin for one year significantly reduces, but not normalises blood cell aggregation.
topic arterial hypertension
dyslipidemia
fluvastatin
aggregation activity
blood cells
url https://cardiovascular.elpub.ru/jour/article/view/150
work_keys_str_mv AT inmedvedev fluvastatineffectsonbloodcellaggregationinpatientswitharterialhypertensionanddyslipidemia
AT iaskoryatina fluvastatineffectsonbloodcellaggregationinpatientswitharterialhypertensionanddyslipidemia
_version_ 1721271051603673088